ORIGINAL CONTRIBUTIONS: LIVER: EDITORIALItching to Know: Role of Fibrates in PBCLevy, Cynthia MD, AGAF, FAASLD1; Lindor, Keith D MD, FAASLD2Author Information 1Division of Hepatology, University of Miami Miller School of Medicine, Miami, Florida, USA 2Arizona State University, Mayo Clinic, Phoenix, Arizona, USA Correspondence: Cynthia Levy, MD, AGAF, FAASLD, Associate Professor of Medicine, Department of Medicine, Division of Hepatology, Center for Liver Diseases, University of Miami Miller School of Medicine, 1500 NW 12th Avenue, Suite 1101, Miami, Florida 33136, USA. E-mail: [email protected] Received 26 September 2017; accepted 4 October 2017 American Journal of Gastroenterology: January 2018 - Volume 113 - Issue 1 - p 56-57 doi: 10.1038/ajg.2017.432 Buy Metrics Abstract Approximately one-third of patients with primary biliary cholangitis (PBC) fail to respond to ursodeoxycholic acid (UDCA) and are at risk for progression to biliary cirrhosis and end-stage liver disease. In this paper by Pareset al., the authors evaluate the effect of long-term use of bezafibrate in patients with primary biliary cholangitis (PBC) and inadequate response to UDCA. They found that addition of bezafibrate led to normalization of serum alkaline phosphatase in half of the study subjects and major improvement in pruritus. Here we discuss these findings and place them in context with current knowledge about fibrates in PBC. © The American College of Gastroenterology 2018. All Rights Reserved.